| Objective: By way of testing Protein S(PROS1)2148A/G and 2698C/A polymorphisms and plasma Protein S levels in Patients with LEDVT to determine the influence of the gene mutation in the development of LEDVT.Methods : In order to undertake a case-control study, 220 LEDVT hospitalized patients(case group) and 248 normal subjects(control group) were studied. Basic clinical data such as age, gender were collected; biochemical parameters such as serum creatinine, urea nitrogen, fasting plasma glucose, lipids,ApolipoproteinA1,ApolipoproteinB were measured. Plasma Protein S levels were determined by Elisa method. Polymerase chain reaction(PCR) and restriction fragment length polymorphism(RFLP) were used to characterize PROS1 2148A/G genotypes(AA, AG, GG). Both of them were confirmed by DNA sequencing. PROS1 2698C/A genetypes were confirmed by DNA sequencing. T(t') test, analysis of variance ,Chi-square test and Logistic regression were used to analyze the data.Result: 1.The levels of fasting plasma glucose,urea nitrogen, ApolipoproteinB had significant differences between two groups (P<0.01), and the levels of age,gender, triglyceride,total cholesterol,low-density lipoprotein cholesterol, serum creatinine, ApolipoproteinA1 had no significant differences between two groups(P>0.05).2. LEDVT develope more common in people with age above 50, especially with age 71-80.Left lower limb was more common site than the right one(2.92:1). 3.The distributions of 2148A allele and 2698A allele in control group(0.556,0.329 respectively) were higher than the ones in LEDVT group(0.464,0.252 respectively). Chi-square test showed that the differences were significant(P<0.05). 4. Both the plasma tPS and fPS levels in LEDVT were significantly lower than that of healthy controls, 16.93±4.07μg/ml versus 23.46±4.67μg/ml(P<0.01), 6.67±1.38μg/ml versus 9.32±2.03μg/ml(P<0.01). In both control group and LEDVT group, the Plasma tPS and fPS levels with 2148A allele were higher than that of without 2148A allele, 23.90±5.12μg/ml versus 21.52±4.26μg/ml(P<0.01),17.43±4.02μg/ml versus 15.65±4.12μg/ml(P<0.01) and 9.58±2.31μg/ml versus 8.19±2.42μg/ml(P<0.01),6.94±1.41μg/ml versus 6.01±1.43μg/ml(P<0.01)respectively. In both control group and LEDVT group, the Plasma tPS and fPS levels with 2698A allele were higher than that of without 2698A allele, 24.50±5.12μg/ml versus 22.37±4.63μg/ml(P<0.01),18.35±5.16μg/ml versus 15.97±3.67μg/ml(P<0.01) and 9.89±2.52μg/ml versus 8.72±2.18μg/ml(P<0.01),7.23±1.76μg/ml versus 6.29±1.89μg/ml(P<0.01)respectively.5. Binary Logistic regression showed that age, 2148A/G–GG,2698C/A–CC,2148A/G–GG +2698C/A–CC genotypes were entered the equation at last and were significantly associated with LEDVT by adjusting other confounding factors (P<0.05). The odds ratios(OR) were 1.056(95%CI:1.035-1.077),2.843(95%CI:1.016-7.955),1.982(95%CI:0.935-4.201),7.257(95%CI:2.874-18.324) respectively.Conclusions: 1. Lowerextremity deep venous thrombosis develope more frequently in subjects with advancing age. Left lower limb was more easily affected site than the right one. 2. Lower plasma PS levels is a risk factor for LEDVT. 3.Both 2148G allele and 2698A allele maybe associated with LEDVT respectively. Subjects carrying 2148G allele and 2698C allele at the same time were exposed to greater risk of LEDVT than ones without carring it. 4. Plasma PS levels is regulated by PROS1 2148A/G and 2698C/A polymorphisms.
|
PDF Full Text Request